WO2011129792A1 - Water dispersible formulations comprising cefpodoxime proxetil - Google Patents

Water dispersible formulations comprising cefpodoxime proxetil Download PDF

Info

Publication number
WO2011129792A1
WO2011129792A1 PCT/TR2011/000092 TR2011000092W WO2011129792A1 WO 2011129792 A1 WO2011129792 A1 WO 2011129792A1 TR 2011000092 W TR2011000092 W TR 2011000092W WO 2011129792 A1 WO2011129792 A1 WO 2011129792A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
composition according
agent
cellulose
sodium
Prior art date
Application number
PCT/TR2011/000092
Other languages
French (fr)
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2011129792A1 publication Critical patent/WO2011129792A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Definitions

  • the present invention relates to pharmaceutical formulations comprising cefpodoxime proxetil.
  • Background of the invention :
  • Cefpodoxime proxetil (figure 1), which has the chemical name pivaloyloxymethyl 7-[2-(2- amino-thiazol-4-yl] -2-(syn)-memoxyimino-acetamido] -3 -methoxymethyl-3 -cephem-4- carboxylate, was first disclosed in the patent numbered EP0049118.
  • Cefpodoxime is a third generation cephalosporin and for that reason, it is indicated for use in the treatment of infections caused by gram positive and gram negative bacteria.
  • Cefpodoxime proxetil is available in oral tablet and oral suspension forms on the market. Cefpodoxime proxetil is a molecule which has a very low solubility in water. Therefore, oral bioavailability of the tablet form is 50% less than cefpodoxime given intravenously.
  • Cefpodoxime proxetil is a hydrophobic molecule and has a water contact angle greater than 90°. Therefore, cefpodoxime proxetil has a low solubility and when used in a pharmaceutical composition has poor disintegration in water.
  • Patent application numbered in WO/2002/067943 relates to pharmaceutical compositions which are suitable for oral use and which comprise cefpodoxime proxetil and pharmaceutical carrier which cefpodoxime is adsorbed on. Said patent application aims to solve the low solubility and slow dispersion of cefpodoxime proxetil.
  • cefpodoxime proxetil exhibits gel formation and forms a gelatinous mass when in contact with aqueous media. Therefore, the gel formation results in poor disintegration and slow dissolution and hence absorption of cefpodoxime from the gastro-intestinal tract and its bioavailability is greatly reduced.
  • the subject matter of the present invention is related to water dispersible tablet and granule formulations comprising cefpodoxime proxetil.
  • the present invention relates to the formulation and preparation procedures of these products.
  • cellulose- based viscosity agent is used and the ratio of viscosity agent: diluent used in the formulation is in the range of 1:5 and 1:10, it is surprisingly observed that water dispersible tablet and granule formulations comprising cefpodoxime proxetil do not exhibit gel formation, dissolve in water entirely and provide high absorption and thus bio-availability of cefpodoxime proxetil.
  • the first aspect of the present invention is that said water dispersible tablet and granule formulations comprising cefpodoxime proxetil comprise cellulosed based viscosity agent and diluent in an amount such that viscosity agent: diluent ratio is in the range of 1 :5 and 1:10.
  • excipients selected from, but not limited to, a group comprising binders, glidants, lubricants, humectants, disintegrants, diluents, basic agents, acidic agents, taste regulating agents, viscosity agents, flavoring agents and optionally effervescent couple can be used in water dispersible tablet and granule formulations in addition to cefpodoxime proxetil.
  • the cellulose-based viscosity agent that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising carboxymethyl cellulose sodium, carboxymethyl cellulose calcium, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxymethyl cellulose, hypromellose or combinations thereof.
  • viscosity agent is selected from hydroxypropyl cellulose, carboxymethyl cellulose sodium, carboxymethyl cellulose calcium or a binary/ternary combination thereof. More preferably a combination of hydroxypropyl cellulose, carboxymethyl cellulose sodium, and carboxymethyl cellulose calcium is used in the formulations pertaining to the present invention.
  • hydroxypropyl cellulose: carboxymethyl cellulose sodium: carboxymethyl cellulose calcium ratio is an important criteria for the solubility of cefpodoxime proxetil and the dissolution of the formulation comprising cefpodoxime proxetil.
  • hydroxypropyl cellulose: carboxymethyl cellulose sodium: carboxymethyl cellulose calcium ratio is in the range of 1: 1: 1 and 1: 8: 9, preferably 1: 2: 3 and 1: 6: 8 and more preferably 1: 3: 4 and 1: 5: 6, the formulation comprising cefpodoxime proxetil pertaining to the present invention has dispersed entirely and formed a homogeneous solution.
  • a viscosity agent mixture comprising hydroxypropyl cellulose, carboxymethyl cellulose sodium and carboxymethyl cellulose calcium in an amount such that hydroxypropyl cellulose : carboxymethyl cellulose sodium : carboxymethyl cellulose calcium ratio is in the range of 1 : 1: 1 and 1 : 8: 9, preferably 1 : 2: 3 and 1: 6: 8 and more preferably 1: 3: 4 and 1 : 5: 6 is used.
  • the diluent that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising calcium carbonate, calcium sulphate, dibasic calcium phosphate, tribasic calcium phosphate, calcium phosphate, calcium sulphate, microcrystalline cellulose, lactose, magnesium carbonate, magnesium oxide, maltodextrin, maltose, mannitol, sodium chloride, sorbitol, starch and xylitol or combinations thereof.
  • lactose is used as the diluent in the formulations pertaining to the present invention.
  • said water dispersible tablet and granule formulations wherein cefpodoxime proxetil is used as an active agent comprise a combination of hydroxypropyl cellulose, carboxymethyl cellulose sodium and carboxymethyl cellulose calcium as viscosity agent mixture and lactose as diluent in an amount such that viscosity agent mixture: lactose ratio is in the range of 1 :5 and 1:10.
  • the binder that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising ethyl cellulose, gelatine, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hypromellose, magnesium aluminum silicate, methyl cellulose, povidone or combinations thereof.
  • the lubricant that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising calcium stearate, magnesium stearate, polyethylene glycol, PEG 6000, polyvinyl alcohol, potassium benzoate, talc, sodium benzoate or a combination thereof.
  • talc is used as the lubricant in the formulations pertaining to the present invention.
  • the glidant that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising magnesium silicate, silicon dioxide, starch, talc, tribasic calcium phosphate or a combination thereof.
  • silicon dioxide is used as the glidant in the formulations pertaining to the present invention.
  • the disintegrant that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, microcrystalline cellulose, silicon dioxide, croscarmellose sodium, crospovidone, hydroxypropyl cellulose, methyl cellulose, povidone, magnesium aluminum silicate and starch or combinations thereof.
  • the taste regulating agent that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising acesulfame, aspartame, dextrose, fructose, glucose, lactitol, maltitol, maltose, sorbitol, saccharine, saccharine sodium, sodium cyclamate, sucralose, sodium chloride, potassium chloride, sucrose, xylitol or combinations thereof.
  • sucrose, aspartame, sodium chloride or a combination thereof is used in the formulations according to the present invention.
  • the basic agent that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising potassium carbonate, potassium bicarbonate, potassium citrate, potassium hydroxide, sodium carbonate, sodium bicarbonate or combinations thereof.
  • the acidic agent that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising acetic acid, citric acid, lactic acid, malic acid, phosphoric acid, propionic acid, tartaric acid or combinations thereof.
  • citric acid is used as the acidic agent in the formulations prepared according to the present invention.
  • Effervescent acid used in the present invention can be selected from organic acids such as citric acid, tartaric acid, malic acid, fumaric acid, ascorbic acid, adipic acid and succinic acid. Citric acid is preferably used.
  • Effervescent base used in the present invention can be selected from basic agents such as sodium hydrogen carbonate, sodium carbonate, potassium carbonate potassium hydrogen carbonate, sodium glycine carbonate, lysine carbonate, arginine carbonate and calcium carbonate. Sodium hydrogen carbonate is preferably used.
  • cefpodoxime proxetil in water dispersible tablet and granule formulation of the present invention, cefpodoxime proxetil can be used in the form of its pharmaceutically acceptable salts, hydrates, solvates or combinations thereof.
  • the water dispersible tablet and granule formulation of the present invention can contain 5- 50% cefpodoxime proxetil or its pharmaceutically acceptable salts, hydrates, solvates or combinations thereof with respect to the total amount of unit dose.
  • the water dispersible tablet and granule formulation of the present invention can comprise 5- 50% cefpodoxime proxetil, 0-30% binder, 0.5-4% glidant, 1-7% lubricant, 0-15% disintegrant and or disintegrants, 1-65% diluent, 1-25% taste regulating agent, 0-20% basic agent, 0.1- 25% acidic agent, 2-15% viscosity agent and/or viscosity agents, 0.1-3% flavoring agents and 0-80% effervescent couple with respect to the total amount of unit dose.
  • the total amount of one or more viscosity agents contained water dispersible formulation of the present invention is in the range of 2-15%, preferably in the range of 5- 12%, more preferably in the range of 7-10 %.
  • the ratio of acidic agent to cefpodoxime proxetil that is used as active agent is in the range of 1:2 to 1:15 in water dispersible formulations according to the present invention. It has been seen that the solubility of the formulation in water has increased upon using acidic agent in the amount specified above.
  • the present invention relates to processes which can be used for the preparation of water dispersible formulations that are suitable for use as single dose and that comprise pharmaceutically acceptable excipients in addition to cefpodoxime proxetil that is used as active agent.
  • the process of the present invention comprises the granulation of cefpodoxime proxetil through conventional wet and/or dry granulation methods; or dry blending of cefpodoxime proxetil and other excipients to obtain powder and optionally compressing the obtained powder in tablet form.
  • the water dispersible pharmaceutical formulation prepared according to the invention is used for the treatment of the diseases relative to the upper respiratory tract infections such as pharangitis, tonsillitis, otitis media; lower respiratory tract infections such as acute pneumonia, acute and chronic broncihia and urinary tract infections such as acute cystitis and cystourethritis.
  • upper respiratory tract infections such as pharangitis, tonsillitis, otitis media
  • lower respiratory tract infections such as acute pneumonia, acute and chronic broncihia
  • urinary tract infections such as acute cystitis and cystourethritis.
  • Water dispersible formulations according to present invention can be prepared according to the examples given below. The examples are given for demonstration of the invention and the invention cannot be limited to these.
  • EXAMPLE 1 Formulation and process for the preparation of water dispersible granules
  • a process for preparation of water dispersible granule given in the example comprises dissolving cefpodoxime proxetil in a suitable solvent and granulation of the diluent and taste regulating agent with this solution and then drying these granules and mixing them with viscosity agent, lubricant, glidant and acidic agent.
  • EXAMPLE 2 Formulation and process for the preparation of effervescent tablet
  • Flavoring agent 1.5% The formulation to be used in scope of the present invention can be obtained by granulation of the effervescent couple, taste regulating agent and the binder with the granulation solution comprising diluent. The granules are then dried and mixed with cefpodoxime proxetil. Following this, the flavoring agent, viscosity agent and the lubricant are added to the blend. The obtained mixture is then compressed in tablet compressing machine to obtain tablets.

Abstract

The present invention relates to pharmaceutical formulations comprising cefpodoxime proxetil.

Description

WATER DISPERSIBLE FORMULATIONS COMPRISING CEFPODOXIME
PROXETIL
The present invention relates to pharmaceutical formulations comprising cefpodoxime proxetil. Background of the invention:
Cefpodoxime proxetil (figure 1), which has the chemical name pivaloyloxymethyl 7-[2-(2- amino-thiazol-4-yl] -2-(syn)-memoxyimino-acetamido] -3 -methoxymethyl-3 -cephem-4- carboxylate, was first disclosed in the patent numbered EP0049118.
Figure imgf000002_0001
Figure 1
Cefpodoxime is a third generation cephalosporin and for that reason, it is indicated for use in the treatment of infections caused by gram positive and gram negative bacteria.
Cefpodoxime proxetil is available in oral tablet and oral suspension forms on the market. Cefpodoxime proxetil is a molecule which has a very low solubility in water. Therefore, oral bioavailability of the tablet form is 50% less than cefpodoxime given intravenously.
Tablets which contain 100 mg and 200 mg of cefpodoxime are available on the market. When these tablets containing 100 or 200 mg of active agent are formulated with excipients, they become too large in size and this makes the use of this dosage form inconvenient for patients who have swallowing difficulties, especially for pediatric and geriatric patients. Alternatively, the use of reliable and user-friendly water dispersible forms is suggested. Cefpodoxime proxetil is a hydrophobic molecule and has a water contact angle greater than 90°. Therefore, cefpodoxime proxetil has a low solubility and when used in a pharmaceutical composition has poor disintegration in water.
In the prior art, several methods have been developed in order to solve the solubility problem of cefpodoxime proxetil in water and increase the disintegration rate and thus absorption of it. Patent application numbered in WO/2002/067943 relates to pharmaceutical compositions which are suitable for oral use and which comprise cefpodoxime proxetil and pharmaceutical carrier which cefpodoxime is adsorbed on. Said patent application aims to solve the low solubility and slow dispersion of cefpodoxime proxetil. However, in these alternatively developed formulations comprising cefpodoxime proxetil in the prior art, solubility problem has been tried to be solved to some extent but it has been observed that cefpodoxime proxetil exhibits gel formation and forms a gelatinous mass when in contact with aqueous media. Therefore, the gel formation results in poor disintegration and slow dissolution and hence absorption of cefpodoxime from the gastro-intestinal tract and its bioavailability is greatly reduced.
As it is seen, new formulations are required to be developed to overcome the solubility and gelling problems of cefpodoxime proxetil and obtain new drugs, which can dissolve quickly in water, which do not exhibit gel formation in water and which can be easily absorbed in the gastro-intestinal tract. The inventors have surprisingly obtained water dispersible tablet and granule formulations comprising cefpodoxime proxetil which overcome the problems that are encountered in the prior art , in other words which can easily dissolve, which can disperse completely and which does not show gelling behavior when dispersed in water.
Description of the invention: The subject matter of the present invention is related to water dispersible tablet and granule formulations comprising cefpodoxime proxetil. In another aspect, the present invention relates to the formulation and preparation procedures of these products. In cases where cellulose- based viscosity agent is used and the ratio of viscosity agent: diluent used in the formulation is in the range of 1:5 and 1:10, it is surprisingly observed that water dispersible tablet and granule formulations comprising cefpodoxime proxetil do not exhibit gel formation, dissolve in water entirely and provide high absorption and thus bio-availability of cefpodoxime proxetil.
Accordingly, the first aspect of the present invention is that said water dispersible tablet and granule formulations comprising cefpodoxime proxetil comprise cellulosed based viscosity agent and diluent in an amount such that viscosity agent: diluent ratio is in the range of 1 :5 and 1:10.
Various excipients selected from, but not limited to, a group comprising binders, glidants, lubricants, humectants, disintegrants, diluents, basic agents, acidic agents, taste regulating agents, viscosity agents, flavoring agents and optionally effervescent couple can be used in water dispersible tablet and granule formulations in addition to cefpodoxime proxetil.
The cellulose-based viscosity agent that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising carboxymethyl cellulose sodium, carboxymethyl cellulose calcium, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxymethyl cellulose, hypromellose or combinations thereof. Preferably, viscosity agent is selected from hydroxypropyl cellulose, carboxymethyl cellulose sodium, carboxymethyl cellulose calcium or a binary/ternary combination thereof. More preferably a combination of hydroxypropyl cellulose, carboxymethyl cellulose sodium, and carboxymethyl cellulose calcium is used in the formulations pertaining to the present invention. The inventors have found that hydroxypropyl cellulose: carboxymethyl cellulose sodium: carboxymethyl cellulose calcium ratio is an important criteria for the solubility of cefpodoxime proxetil and the dissolution of the formulation comprising cefpodoxime proxetil. In cases where hydroxypropyl cellulose: carboxymethyl cellulose sodium: carboxymethyl cellulose calcium ratio is in the range of 1: 1: 1 and 1: 8: 9, preferably 1: 2: 3 and 1: 6: 8 and more preferably 1: 3: 4 and 1: 5: 6, the formulation comprising cefpodoxime proxetil pertaining to the present invention has dispersed entirely and formed a homogeneous solution.
According to this, another aspect of the present invention is that a viscosity agent mixture comprising hydroxypropyl cellulose, carboxymethyl cellulose sodium and carboxymethyl cellulose calcium in an amount such that hydroxypropyl cellulose : carboxymethyl cellulose sodium : carboxymethyl cellulose calcium ratio is in the range of 1 : 1: 1 and 1 : 8: 9, preferably 1 : 2: 3 and 1: 6: 8 and more preferably 1: 3: 4 and 1 : 5: 6 is used. The diluent that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising calcium carbonate, calcium sulphate, dibasic calcium phosphate, tribasic calcium phosphate, calcium phosphate, calcium sulphate, microcrystalline cellulose, lactose, magnesium carbonate, magnesium oxide, maltodextrin, maltose, mannitol, sodium chloride, sorbitol, starch and xylitol or combinations thereof. Preferably, lactose is used as the diluent in the formulations pertaining to the present invention.
Accordingly, another aspect of the present invention is that said water dispersible tablet and granule formulations wherein cefpodoxime proxetil is used as an active agent comprise a combination of hydroxypropyl cellulose, carboxymethyl cellulose sodium and carboxymethyl cellulose calcium as viscosity agent mixture and lactose as diluent in an amount such that viscosity agent mixture: lactose ratio is in the range of 1 :5 and 1:10.
The binder that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising ethyl cellulose, gelatine, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hypromellose, magnesium aluminum silicate, methyl cellulose, povidone or combinations thereof.
The lubricant that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising calcium stearate, magnesium stearate, polyethylene glycol, PEG 6000, polyvinyl alcohol, potassium benzoate, talc, sodium benzoate or a combination thereof. Preferably, talc is used as the lubricant in the formulations pertaining to the present invention.
The glidant that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising magnesium silicate, silicon dioxide, starch, talc, tribasic calcium phosphate or a combination thereof. Preferably, silicon dioxide is used as the glidant in the formulations pertaining to the present invention.
The disintegrant that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, microcrystalline cellulose, silicon dioxide, croscarmellose sodium, crospovidone, hydroxypropyl cellulose, methyl cellulose, povidone, magnesium aluminum silicate and starch or combinations thereof. The taste regulating agent that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising acesulfame, aspartame, dextrose, fructose, glucose, lactitol, maltitol, maltose, sorbitol, saccharine, saccharine sodium, sodium cyclamate, sucralose, sodium chloride, potassium chloride, sucrose, xylitol or combinations thereof. Preferably, sucrose, aspartame, sodium chloride or a combination thereof is used in the formulations according to the present invention.
The basic agent that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising potassium carbonate, potassium bicarbonate, potassium citrate, potassium hydroxide, sodium carbonate, sodium bicarbonate or combinations thereof.
The acidic agent that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising acetic acid, citric acid, lactic acid, malic acid, phosphoric acid, propionic acid, tartaric acid or combinations thereof. Preferably, citric acid is used as the acidic agent in the formulations prepared according to the present invention.
Effervescent acid used in the present invention can be selected from organic acids such as citric acid, tartaric acid, malic acid, fumaric acid, ascorbic acid, adipic acid and succinic acid. Citric acid is preferably used. Effervescent base used in the present invention can be selected from basic agents such as sodium hydrogen carbonate, sodium carbonate, potassium carbonate potassium hydrogen carbonate, sodium glycine carbonate, lysine carbonate, arginine carbonate and calcium carbonate. Sodium hydrogen carbonate is preferably used.
In water dispersible tablet and granule formulation of the present invention, cefpodoxime proxetil can be used in the form of its pharmaceutically acceptable salts, hydrates, solvates or combinations thereof.
The water dispersible tablet and granule formulation of the present invention can contain 5- 50% cefpodoxime proxetil or its pharmaceutically acceptable salts, hydrates, solvates or combinations thereof with respect to the total amount of unit dose. The water dispersible tablet and granule formulation of the present invention can comprise 5- 50% cefpodoxime proxetil, 0-30% binder, 0.5-4% glidant, 1-7% lubricant, 0-15% disintegrant and or disintegrants, 1-65% diluent, 1-25% taste regulating agent, 0-20% basic agent, 0.1- 25% acidic agent, 2-15% viscosity agent and/or viscosity agents, 0.1-3% flavoring agents and 0-80% effervescent couple with respect to the total amount of unit dose.
In another aspect, the total amount of one or more viscosity agents contained water dispersible formulation of the present invention is in the range of 2-15%, preferably in the range of 5- 12%, more preferably in the range of 7-10 %.
In another aspect, the ratio of acidic agent to cefpodoxime proxetil that is used as active agent is in the range of 1:2 to 1:15 in water dispersible formulations according to the present invention. It has been seen that the solubility of the formulation in water has increased upon using acidic agent in the amount specified above.
In another aspect, the present invention relates to processes which can be used for the preparation of water dispersible formulations that are suitable for use as single dose and that comprise pharmaceutically acceptable excipients in addition to cefpodoxime proxetil that is used as active agent.
Accordingly, the process of the present invention comprises the granulation of cefpodoxime proxetil through conventional wet and/or dry granulation methods; or dry blending of cefpodoxime proxetil and other excipients to obtain powder and optionally compressing the obtained powder in tablet form.
Another aspect of the present invention is that the water dispersible pharmaceutical formulation prepared according to the invention is used for the treatment of the diseases relative to the upper respiratory tract infections such as pharangitis, tonsillitis, otitis media; lower respiratory tract infections such as acute pneumonia, acute and chronic broncihia and urinary tract infections such as acute cystitis and cystourethritis.
Water dispersible formulations according to present invention can be prepared according to the examples given below. The examples are given for demonstration of the invention and the invention cannot be limited to these. EXAMPLE 1 : Formulation and process for the preparation of water dispersible granules
Figure imgf000008_0001
A process for preparation of water dispersible granule given in the example comprises dissolving cefpodoxime proxetil in a suitable solvent and granulation of the diluent and taste regulating agent with this solution and then drying these granules and mixing them with viscosity agent, lubricant, glidant and acidic agent.
EXAMPLE 2: Formulation and process for the preparation of effervescent tablet
% of amount present in unit dose
Cefpodoxime proxetil 13.5%
Effervescent acid 33%
Effervescent Base 31%
Binder 1%
Diluent 14 %
Viscosity agent 2.5%
Taste regulating agent 1.5%
Lubricant 2.0%
Flavoring agent 1.5% The formulation to be used in scope of the present invention can be obtained by granulation of the effervescent couple, taste regulating agent and the binder with the granulation solution comprising diluent. The granules are then dried and mixed with cefpodoxime proxetil. Following this, the flavoring agent, viscosity agent and the lubricant are added to the blend. The obtained mixture is then compressed in tablet compressing machine to obtain tablets.

Claims

1. A pharmaceutical composition formulated in water dispersible tablet and granule form comprising cefpodoxime proxetil characterized in that in said composition viscosity agent is cellulose-based and the ratio of viscosity agent to diluent is in the range of 1:5 to 1 :10.
2. The pharmaceutical composition according to claim 1, wherein cefpodoxime proxetil that is used as the active agent can be in the form of its pharmaceutically acceptable salts, hydrates, solvates or combinations thereof.
3. The pharmaceutical composition according to claim 1, wherein the cellulose-based viscosity agent is selected from a group comprising carboxymethyl cellulose sodium, carboxymethyl cellulose calcium, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxymethyl cellulose, hypromellose or combinations thereof.
4. The pharmaceutical composition according to claim 3, wherein cellulose-based viscosity agent is selected from a group comprising hydroxypropyl cellulose, carboxymethyl cellulose sodium, carboxymethyl cellulose calcium and binary/ternary combinations thereof.
5. The pharmaceutical composition according to claim 4, wherein cellulose-based viscosity agent is a viscosity agent mixture comprising the combination of hydroxypropyl cellulose, carboxymethyl cellulose sodium and carboxymethyl cellulose calcium.
6. The pharmaceutical composition according to claim 1, wherein the diluent is selected from a group comprising calcium carbonate, calcium sulphate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulphate, microcrystalline cellulose, lactose, magnesium carbonate, magnesium oxide, maltodextrin, maltose, mannitol, sodium chloride, sorbitol, starch, xylitol or combinations thereof.
7. The pharmaceutical composition according to claim 6, wherein lactose is used as diluent.
8. The pharmaceutical composition according to claim 1, wherein said composition further comprises other pharmaceutically acceptable excipients in addition to viscosity agent and diluent that is used together with cefpodoxime proxetil.
9. The pharmaceutical composition according to claim 8, wherein said composition comprises one or more binders, glidant, lubricant, humectant, disintegrant, basic agent, acidic agent, taste regulating agent, flavoring agent and optionally effervescent couple in addition to viscosity agent and diluent that is used together with cefpodoxime proxetil.
10. The pharmaceutical composition according to claim 9, wherein the binder is selected from a group comprising ethyl cellulose, gelatine, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hypromellose, magnesium duminum silicate, methyl cellulose, povidone or combinations thereof.
11. The pharmaceutical composition according to claim 9, wherein the lubricant is selected from a group comprising calcium stearate, magnesium stearate, polyethylene glycol, PEG 6000, polyvinyl alcohol, potassium benzoate, talc, sodium benzoate or combinations thereof.
12. The pharmaceutical composition according to claim 9, wherein the glidant is selected from a group comprising silicon dioxide, starch, talc, tribasic calcium phosphate or combinations thereof.
13. The pharmaceutical composition according to claim 9, wherein the disintegrant is selected from a group comprising carboxymethyl cellulose calcium, carboxymethylcellulose sodium, silicon dioxide, croscarmellose sodium, crospovidone, hydroxypropyl cellulose, methyl cellulose, povidone, magnesium aluminum silicate, starch or combinations thereof.
14. The pharmaceutical composition according to claim 9, wherein the basic agent is selected from a group comprising potassium carbonate, potassium bicarbonate, potassium citrate, potassium hydroxide, sodium carbonate, sodium bicarbonate or combinations thereof.
15. The pharmaceutical composition according to claim 9, wherein the acidic agent is selected from a group comprising acetic acid, citric acid, lactic acid, malic acid, phosphoric acid, propionic acid, tartaric acid or combinations thereof.
16. The pharmaceutical composition according to claim 15, wherein citric acid is used as acidic agent.
17. The pharmaceutical composition according to claim 9, wherein the taste regulating agent is selected from a group comprising acesulfame, aspartame, dextrose, fructose, glucose, lactitol, maltitol, sorbitol, saccharine sodium, sodium cyclamate, sucralose, sodium chloride, potassium chloride, sucrose, xylitol or combinations thereof.
18. The pharmaceutical composition according to claim 17, wherein saccharose, aspartame, sodium chloride or combinations thereof is used as taste regulating agent.
19. The pharmaceutical composition according to claim 9, wherein the effervescent acid is selected from organic acids such as citric acid, tartaric acid, malic acid, fumaric acid, ascorbic acid, adipic acid and succinic acid.
20. The pharmaceutical composition according to claim 19, wherein citric acid is used as effervescent acid.
21. The pharmaceutical composition according to claim 9, wherein the effervescent base is selected from basic agents such as sodium hydrogen carbonate, sodium carbonate, potassium carbonate, potassium bicarbonate, potassium hydrogen carbonate, sodium glycine carbonate, lysine carbonate, arginine carbonate and calcium carbonate.
22. The pharmaceutical composition according to claim 21, wherein sodium hydrogen carbonate is used as effervescent base.
23. The pharmaceutical composition according to claim 1, wherein said composition comprises cefpodoxime proxetil or its pharmaceutically acceptable solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystal and amorphous forms in an amount equivalent to 5-50% of the unit dose.
24. The pharmaceutical composition according to claim 1, wherein the total amount of one or more viscosity agents used in said composition is 2-15 % with respect to total weight of the unit dose.
25. The pharmaceutical composition according to claim 24, wherein the total amount of one or more viscosity agents used in said composition is 5-12 % with respect to total weight of the unit dose.
26. The pharmaceutical composition according to claim 25, wherein the total amount of one or more viscosity agents used in said composition is 7-10% with respect to total weight of the unit dose.
27. The pharmaceutical composition according to claim 15, wherein the ratio of the acidic agent to cefpodoxime proxetil is in the range of 1 :2 to 1:15.
28. The pharmaceutical composition according to claim 1, wherein said composition comprises 5-50% cefpodoxime proxetil, 0-30% binder, 0.5-4% glidant, 1-7% lubricant, 0-15% disintegrant and/or disintegrants, 1-65% diluent, 1-25% taste regulating agent, 0-20% basic agent, 0.1-25% acidic agent, 2-15% viscosity agent and/or viscosity agents, 0.1-3% flavoring agents and 0-80% effervescent couple with respect to the total amount of unit dose.
29. The process for preparation of a pharmaceutical composition according to the preceding claims, wherein said process comprises granulation of cefpodoxime proxetil through conventional wet and/or dry granulation methods; or dry blending cefpodoxime proxetil and other excipients to obtain a powder and compressing these in tablet compressing machine to obtain tablet forms.
PCT/TR2011/000092 2010-04-13 2011-04-13 Water dispersible formulations comprising cefpodoxime proxetil WO2011129792A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/02878 2010-04-13
TR2010/02878A TR201002878A2 (en) 2010-04-13 2010-04-13 Pharmaceutical compositions comprising cefpodoxime proxetil.

Publications (1)

Publication Number Publication Date
WO2011129792A1 true WO2011129792A1 (en) 2011-10-20

Family

ID=44279055

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000092 WO2011129792A1 (en) 2010-04-13 2011-04-13 Water dispersible formulations comprising cefpodoxime proxetil

Country Status (2)

Country Link
TR (1) TR201002878A2 (en)
WO (1) WO2011129792A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012060786A3 (en) * 2010-11-05 2012-07-26 Mahmut Bilgic Cefpodoxime proxetil formulations comprising viscosity agent
WO2012026908A3 (en) * 2010-08-25 2012-09-07 Mahmut Bilgic Cefpodoxime proxetil formulations comprising taste regulating agent
WO2012026907A3 (en) * 2010-08-25 2012-09-13 Mahmut Bilgic Cefpodoxime proxetil formulations
CN103142506A (en) * 2013-04-03 2013-06-12 天津医药集团津康制药有限公司 Cefpodoxime proxetil granules and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0049118A2 (en) 1980-09-30 1982-04-07 Sankyo Company Limited Cephalosporin derivatives, their preparation and compositions containing them
WO2002067943A1 (en) 2001-02-27 2002-09-06 Ranbaxy Laboratories Limited Oral pharmaceutical composition of cefpodoxime proxetil
WO2004006917A1 (en) * 2002-07-16 2004-01-22 Ranbaxy Laboratories Limited Dispersible tablets for oral administration
JP2004043475A (en) * 2002-07-08 2004-02-12 Sankyo Co Ltd Oral cephalosporin preparation
WO2008057058A1 (en) * 2006-11-10 2008-05-15 Nobel Ilac Sanayii Ve Ticaret As Oral pharmaceutical compositions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0049118A2 (en) 1980-09-30 1982-04-07 Sankyo Company Limited Cephalosporin derivatives, their preparation and compositions containing them
WO2002067943A1 (en) 2001-02-27 2002-09-06 Ranbaxy Laboratories Limited Oral pharmaceutical composition of cefpodoxime proxetil
JP2004043475A (en) * 2002-07-08 2004-02-12 Sankyo Co Ltd Oral cephalosporin preparation
WO2004006917A1 (en) * 2002-07-16 2004-01-22 Ranbaxy Laboratories Limited Dispersible tablets for oral administration
WO2008057058A1 (en) * 2006-11-10 2008-05-15 Nobel Ilac Sanayii Ve Ticaret As Oral pharmaceutical compositions

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012026908A3 (en) * 2010-08-25 2012-09-07 Mahmut Bilgic Cefpodoxime proxetil formulations comprising taste regulating agent
WO2012026907A3 (en) * 2010-08-25 2012-09-13 Mahmut Bilgic Cefpodoxime proxetil formulations
WO2012060786A3 (en) * 2010-11-05 2012-07-26 Mahmut Bilgic Cefpodoxime proxetil formulations comprising viscosity agent
WO2012060790A3 (en) * 2010-11-05 2012-09-20 Mahmut Bilgic Water dispersible cefpodoxime proxetil formulations
CN103142506A (en) * 2013-04-03 2013-06-12 天津医药集团津康制药有限公司 Cefpodoxime proxetil granules and preparation method thereof

Also Published As

Publication number Publication date
TR201002878A2 (en) 2011-10-21

Similar Documents

Publication Publication Date Title
WO2011093833A2 (en) Effervescent formulations comprising second generation cephalosporin
US8614315B2 (en) Cefdinir and cefixime formulations and uses thereof
WO2011129792A1 (en) Water dispersible formulations comprising cefpodoxime proxetil
WO2011139249A2 (en) Pharmaceutical composition comprising cefdinir
EP2515850B1 (en) Pharmaceutical compositions comprising cefdinir as an active agent
EP2515849A1 (en) Effervescent tablet and granule formulation comprising cefixime
WO2012060790A2 (en) Water dispersible cefpodoxime proxetil formulations
WO2012026907A2 (en) Cefpodoxime proxetil formulations
EP2568957A1 (en) Pharmaceutical composition comprising cefixime and clavulanic acid derivative compound
EP2566449B1 (en) Pharmaceutical compositions comprising ceftibuten
WO2011093828A2 (en) Solid dosage forms comprising cefprozil
EP2566451B1 (en) Pharmaceutical compositions comprising cefditoren pivoxil
EP2515859A1 (en) Rapidly dispersing effervescent formulation
WO2012060787A1 (en) Oral dosage forms comprising cefdinir and carboxymethyl cellulose calcium
WO2011139255A2 (en) Pharmaceutical compositions comprising cefetamet
WO2012060791A2 (en) Production method for pharmaceutical compositions comprising cefdinir
WO2012060792A1 (en) Pharmaceutical compositions comprising minimum 6 % of disintegrants by weight
EP2663289A2 (en) Cefpodoxime proxetil formulations comprising taste regulating agent
WO2012078121A2 (en) Solid oral dosage form comprising cefdinir
WO2012060789A2 (en) Production method for cefdinir formulations
EP2833872A1 (en) Tablet formulations comprising cefpodoxime proxetil and clavulanic acid

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11727818

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11727818

Country of ref document: EP

Kind code of ref document: A1